EULAR 2025

Interfering on the long run: less difficult-to-treat…

What about malignancies with JAKi treatment?

Real world data of Adalimumab vs Ixekizumab in PsA

TYK2-Inhibitors a new oral treatment option?

Effect of TNF inhibitors on the risk of cancer…

Sex-specific response on biologics

Impact of biologics on cardiovascular outcome in AS

Cancer reactivation in axSpA patients treated with…

The IL-17 story continues!

Impact of GLP-1 receptor agonists on cardiovascular…

Subjective or objective endpoints - is there a…

Connection between pain and disease activity

Effetti degli inibitori del TNF sul rischio di recidiva…

Krebs-Reaktivierung bei mit TNF-Blockern behandelten…

Zusammenhang von Schmerz und Krankheitsaktivität

Subjektive oder objektive Endpunkte - gibt es eine…

Neue bispezifische Antikörper gegen axSpA?

Die IL-17-Story geht weiter!

Impatto degli agonisti del recettore GLP-1 sugli eventi…

Geschlechtsspezifisches Ansprechen auf Biologika

Real world data of Adalimumab vs Ixekizumab in PsA

TYK2-Inhibitors a new oral treatment option?

Sonelokimab, a novel IL-17A- and IL-17F-inhibiting…

Sexual health in patients with PsA

Hit hard & early or tight control - two ways to reach…

MTX+LEF strategy vs MTX alone in PsA

Definitions and prevalence of difficult-to-treat PsA

Sonelokimab - again IL-17 inhibition or new IL-17…

Difficult-to-treat patients in active PsA

High prevalence of PsA in PsO patients without…

TYK2: convenient, safe and effective!

TYK2 inhibitors in PsA

Sonelokimab, a novel IL-17A- and IL-17F-inhibiting…

TYK2-Inhibitoren bei PsA

IL-23 stoppt radiografischen Progress

Stratégie MTX+LEF vs MTX seul dans le rhumatisme…

Definición y prevalencia de la APs difícil de tratar

Santé sexuelle au cours du rhumatisme psoriasique

Sonelokimab - schon wieder IL-17-Inhibition oder neue…

Hohe Prävalenz von PsA bei PsO-Patienten ohne…

Hit Hard & Early oder Tight Control - zwei Wege zum…

Difficult-to-treat patients in active PsA

Interfering on the long run: less difficult-to-treat…

Preventing, delaying or early sufficient treatment of…

ILD in rheumatoid arthritis

Cancer incidence in RA from the JAK-POT study

New treatment options in RA

Safety of JAKies in RA

Cancer risk under biologic therapy in RA

Abatacept in individuals at risk of delevoping RA

Abatacept en individuos en riesgo de desarrollar AR

Cancer incidence in RA from the JAK-POT study

Risque de cancer sous biomédicament dans la PR

Patient history matters: real-world data of infliximab…

Cancer mortality in inflammatory joint diseases

Cost-effectiveness of therapeutic drug monitoring

New therapeutic approach for refractory myositis

Neuer Therapieansatz für refrakträre Myositis

Cancer mortality in inflammatory joint diseases

Kombinationstherapien bei immunvermittelten…

Die Patientengeschichte zählt: Infliximab-Biosimilar…